BEATRICE GYEBI: Open Payments
NPI 1366816787 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$560 in 21 payments from 8 companies in 2025. Trend: 2023 $436 · 2024 $711 · 2025 $560
Food & beverage: $560
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 2 | $142 |
| ABBVIE INC. | 5 | $139 |
| Novo Nordisk Inc | 5 | $104 |
| AstraZeneca Pharmaceuticals LP | 4 | $65 |
| GlaxoSmithKline, LLC. | 2 | $42 |
| Exact Sciences Corporation | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Optinose US, Inc. | 1 | $20 |
Products named: REPATHA, QULIPTA, UBRELVY, Rybelsus, Ozempic, TRELEGY ELLIPTA, AIRSUPRA, BREZTRI.
Industry payments across TX — which companies pay providers there.
